NICE Approves Home-Use Tablet for Chronic Lymphocytic Leukaemia Patients in England
The National Institute for Health and Care Excellence (NICE) has recommended the use of pirtobrutinib, a take-at-home tablet, for patients with chronic lymphocytic leukaemia (CLL) in England. This recommendation is specifically for patients who have previously been treated with a covalent Bruton’s tyrosine kinase inhibitor (BTKi) and for whom further treatment with a covalent BTKi is not suitable. Pirtobrutinib, an oral medication, offers a new treatment option that reduces the need for hospital visits, providing a more convenient alternative to infusional treatment regimens. The draft guidance highlights that pirtobrutinib is cost-effective compared to other treatments like venetoclax alone or in combination with rituximab. However, it can only be used if further treatment with a BTKi is not clinically suitable. The consultation on this draft guidance is open until May 11, 2026. 
